Traveler's Diarrhea Treatment Global Market Report 2025

The traveler’s diarrhea treatment market size has grown strongly in recent years. It will grow from $1.47 billion in 2024 to $1.6 billion in 2025 at a compound annual growth rate (CAGR) of 8.3%. The growth during the historic period can be attributed to the increasing cases of viral, bacterial, and parasitic infections, a rise in chronic diseases, greater awareness of travel-related illnesses, a higher prevalence of traveler's diarrhea, and an increase in food poisoning incidents.

The traveler’s diarrhea treatment market size is expected to see strong growth in the next few years. It will grow to $2.17 billion in 2029 at a compound annual growth rate (CAGR) of 8%. The projected growth in the forecast period can be attributed to the rising prevalence of food poisoning cases, an increasing number of celiac disease diagnoses, a higher demand for anti-diarrheal medications, the growing popularity of adventure and eco-tourism, and a rise in international travel. Key trends during this period include the development of novel treatments, the use of probiotics and microbiome-based therapies, advancements in rapid diagnostic tools, the introduction of vaccines for prevention, and the continued growth of gastrointestinal drugs.

The growing number of travelers is expected to drive the expansion of the traveler's diarrhea treatment market. Travelers are individuals who move from one location to another, typically for leisure, business, or other reasons. Factors contributing to the rise in travelers include increasing disposable incomes, the growth of budget airlines, simplified visa requirements, and the rising popularity of experiential tourism. Traveler's diarrhea treatments assist by quickly alleviating symptoms, preventing dehydration, and enabling faster recovery, allowing travelers to continue their trips with minimal disruption. For example, in March 2023, the Bureau of Transportation Statistics reported that U.S. airlines transported 853 million passengers in 2022, an increase of 194 million from the 658 million carried in 2021. Consequently, the surge in travel is driving the growth of the traveler's diarrhea treatment market.

The increasing number of food poisoning cases is also expected to fuel the growth of the traveler's diarrhea treatment market. Food poisoning occurs from consuming contaminated food or beverages, often due to bacteria, viruses, parasites, or toxins. The rise in food poisoning cases is linked to factors such as improper food handling, contamination by bacteria such as Salmonella and E. coli, inadequate refrigeration, and a higher consumption of processed and ready-to-eat foods. Treatments for traveler's diarrhea help manage food poisoning symptoms such as dehydration, nausea, and abdominal cramps through rehydration therapy, antimicrobial medications, and probiotics, promoting quicker recovery and reducing complications. In December 2024, the European Food Safety Authority reported that the EU saw 5,763 foodborne outbreaks in 2022, reflecting a 44% increase compared to 2021. As a result, the growing incidence of food poisoning is contributing to the growth of the traveler's diarrhea treatment market.

Companies in the traveler's diarrhea treatment market are also focusing on developing innovative products such as delayed-release tablets to enhance treatment efficacy and reduce dosing frequency. These tablets are designed to release active ingredients at specific times after ingestion, ensuring the medication reaches the intestines before dissolving, which helps treat traveler's diarrhea effectively while minimizing stomach irritation. For example, in September 2023, Adalvo Ltd., based in Malta, partnered with Cosmo Pharmaceuticals N.V., based in Ireland, to launch Rifamycin SV MMX 200 mg (Aemcolo). This medication treats traveler's diarrhea by delivering a non-absorbed antibiotic directly to the colon, alleviating symptoms while minimizing disruption to beneficial gut bacteria. This targeted approach offers effective relief with a lower risk of systemic side effects and multi-drug resistance.

Major players in the traveler's diarrhea treatment market are Johnson & Johnson Services Inc., Bayer AG, Sanofi SA, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., C.H. Boehringer Sohn AG & Co. KG, Astellas Pharma Inc., Aurobindo Pharma Limited, Lupin Pharmaceuticals Inc., Mallinckrodt plc, Glenmark Pharmaceuticals Ltd., Indivior plc, Immuron Limited, Valneva SE, Cosmo Pharmaceuticals N.V., Otsuka Pharmaceutical Co. Ltd., Lumen Bioscience Inc., RedHill Biopharma Ltd., Brown & Burk Pharmaceuticals Ltd., Scandinavian Biopharma Holding AB.

North America was the largest region in the traveler’s diarrhea treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in traveler's diarrhea treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the traveler's diarrhea treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Traveler's diarrhea is a common illness that occurs when individuals consume contaminated food or water while traveling. It is typically marked by frequent, loose stools, abdominal cramps, and sometimes nausea or vomiting. Treatment focuses on rehydration with oral rehydration solutions, the use of anti-diarrheal medications such as loperamide, and antibiotics in more severe cases.

The primary types of drugs used to treat traveler's diarrhea include antibiotics, anti-diarrheal medications, and other drug types. Antibiotics work by treating bacterial infections, either killing bacteria or inhibiting their growth. These drugs are administered through various routes, including oral and parenteral, and are used in treating both adult and children's traveler's diarrhea. The main end users of these medications include hospitals, homecare settings, specialty clinics, and other healthcare providers.

The traveler’s diarrhea treatment market research report is one of a series of new reports that provides traveler’s diarrhea treatment market statistics, including the traveler’s diarrhea treatment industry global market size, regional shares, competitors with the traveler’s diarrhea treatment market share, detailed traveler’s diarrhea treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the traveler’s diarrhea treatment industry. This traveler’s diarrhea treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The traveler's diarrhea treatment market consists of revenues earned by entities by providing services such as probiotics and preventive supplements, telemedicine and online consultations, travel vaccinations and preventive care, medical insurance and assistance services. The market value includes the value of related goods sold by the service provider or included within the service offering. The traveler's diarrhea treatment market also includes sales of oral rehydration salts (ORS), antimotility agents, probiotics, and bismuth subsalicylate products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.